3/19/2020

Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date

Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date

ORION CORPORATION STOCK EXCHANGE RELEASE 19 MARCH 2020 at 12.20 EET             
         

Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date

Due to the development of the coronavirus situation and the announcements by the Finnish Government, Orion’s Board of Directors has decided to cancel the Annual General Meeting convened for Wednesday 25 March 2020.  

Orion takes the coronavirus situation seriously and does not want to jeopardise the health of employees, shareholders and other stakeholders that are attending the Annual General Meeting. The Finnish Government announced on 16 March 2020 that due to the coronavirus situation public gatherings will be limited to a maximum of ten persons. Due to these reasons, the Board of Directors of Orion has decided to cancel the Annual General Meeting convened for 25 March 2020.

Orion’s Board of Directors will convene the Annual General Meeting at a later stage.



Orion Corporation

Timo Lappalainen
President and CEO
 Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   


Contact person:
Tuukka Hirvonen, Investor Relations
tel. +358 50 966 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.